To investigate the efficacy and safety of combining vandetanib , an orally available multi-targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 ( VEGFR-2 ) and epidermal growth factor receptor ( EGFR ) , with bicalutamide in patients with metastatic castration-resistant prostate cancer ( mCRPC ) .